Global Sucralfate Chewable Tablet Market Size By Type (Tablet, Capsule), By Application (Ulcer Healing, Others), By Region, And Segment Forecasts, 2023 to 2032

The Global Sucralfate Chewable Tablet Market was valued at USD 415 million in 2023 and is projected to reach USD 668 million by 2031, expanding at a CAGR of 6.1% during the forecast period (2023–2031). This growth is primarily driven by the rising incidence of gastric ulcers, gastroesophageal reflux disease (GERD), and peptic ulcers globally. Sucralfate chewable tablets are gaining traction due to their convenience in administration and effectiveness in providing localized protection to the gastrointestinal lining. Increased healthcare awareness, growing geriatric population, and expanding over-the-counter (OTC) product availability are further propelling market growth.

Drivers:

1. Rising Prevalence of Gastrointestinal Disorders:

The increasing occurrence of gastrointestinal ailments, such as peptic ulcers and GERD, particularly in aging populations and individuals with high stress or unhealthy dietary habits, is a primary market driver. Sucralfate's ability to provide fast and effective relief boosts its demand.

2. Growing Preference for Chewable Formulations:

Chewable tablets are preferred for ease of use, especially among pediatric and elderly patients who may have difficulty swallowing conventional tablets or capsules. This preference is contributing to increased product adoption.

3. Expanding OTC Availability:

With several formulations of sucralfate tablets becoming available as OTC medications in various regions, access and affordability have significantly improved, widening the market base.

Restraints:

1. Limited Awareness in Developing Regions:

In several low-income countries, there is limited awareness regarding effective ulcer treatments, and access to modern medications remains restricted, posing a challenge to market growth.

2. Availability of Alternative Therapies:

The market faces competition from other treatment options like proton pump inhibitors (PPIs) and H2-receptor antagonists, which are more established and widely used.

Opportunity:

1. Product Innovation and Reformulation:

Opportunities exist in innovating flavor-enhanced or sugar-free formulations of sucralfate chewable tablets to improve palatability and appeal to wider demographic groups.

2. Market Penetration in Emerging Economies:

As healthcare infrastructure improves in emerging markets like India, Brazil, and Southeast Asia, there is a significant opportunity for companies to expand their product reach.

Market by System Type Insights:

Aluminum-based Sucralfate Tablets dominated the market in 2023 due to their proven efficacy in binding to ulcerated tissues and forming a protective barrier. These formulations are well-established and extensively prescribed across hospitals and clinics. Future product development is expected to focus on reducing side effects related to aluminum toxicity while retaining efficacy.

Market by End-use Insights:

Hospitals and Clinics were the leading end-use segment in 2023, driven by physician-prescribed sucralfate formulations for patients with severe gastric disorders. However, the Retail Pharmacies segment is projected to witness the fastest growth due to rising demand for OTC medications and increased patient self-care initiatives.

Market by Regional Insights:

North America accounted for the largest share of the global sucralfate chewable tablet market in 2023, owing to a well-developed healthcare infrastructure, high prevalence of gastrointestinal conditions, and robust consumer awareness. Meanwhile, Asia-Pacific is expected to experience the fastest growth during the forecast period, attributed to rising healthcare spending, increased diagnosis rates, and a growing middle-class population.

Competitive Scenario:

Key players in the global sucralfate chewable tablet market include Pfizer Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Zydus Lifesciences, Cipla Ltd., Sun Pharmaceutical Industries Ltd., and Dr. Reddy’s Laboratories. These companies are engaged in product innovation, regulatory approvals, and regional expansion to strengthen their market positions.

Recent Developments:

In 2023, Zydus launched a new mint-flavored sucralfate chewable tablet in India aimed at enhancing consumer compliance.

Teva received FDA approval in 2024 for its sugar-free chewable sucralfate formulation targeting diabetic ulcer patients.

In 2025, Cipla expanded its OTC digestive care portfolio with a line of chewable gastroprotective tablets across Southeast Asia.

Scope of Work – Global Sucralfate Chewable Tablet Market

Report Metric Details

Market Size (2023) USD 415 million

Projected Market Size (2031) USD 668 million

CAGR (2023–2031) 6.1%

Market Segments By System Type, By End-Use, By Region

Growth Drivers Rising GI disorder prevalence, preference for chewable dosage, OTC expansion

Opportunities Product reformulation, emerging market penetration

Key Market Developments:

2023: Zydus Lifesciences introduced new flavor variants to improve adherence in pediatric patients.

2024: Cipla launched digitally integrated adherence tracking packaging for sucralfate tablets.

2025: Dr. Reddy’s Laboratories expanded its ulcer treatment portfolio with a new sucralfate chewable range across LATAM.

FAQs:

1) What is the current market size of the Global Sucralfate Chewable Tablet Market?

The market was valued at USD 415 million in 2023.

2) What is the major growth driver of the Global Sucralfate Chewable Tablet Market?

The primary growth driver is the increasing prevalence of gastrointestinal disorders and the growing preference for chewable medication formats.

3) Which is the largest region during the forecast period in the Global Sucralfate Chewable Tablet Market?

North America is the largest region due to its advanced healthcare infrastructure and high disease prevalence.

4) Which segment accounted for the largest market share in the Global Sucralfate Chewable Tablet Market?

The hospital and clinics segment led in 2023, owing to higher prescription rates of sucralfate for ulcer treatment.

5) Who are the key market players in the Global Sucralfate Chewable Tablet Market?

Pfizer Inc., Teva Pharmaceuticals, Zydus Lifesciences, Cipla Ltd., Sun Pharma, and Dr. Reddy’s Laboratories are among the major players.

Let me know if you'd like a version of this as a downloadable document or formatted for publication.